Aligos Therapeutics, Inc. (ALGS) Tops Q2 EPS by 19c

Aligos Therapeutics, Inc. (NASDAQ: ALGS) reported Q2 EPS of $0.03, $0.19 better than the analyst estimate of ($0.16).

For earnings history and earnings-related data on Aligos Therapeutics, Inc. (ALGS) click here.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Agroz faces Nasdaq delisting over bid price and filing failures
• Thunder Mountain Gold closes $5.7M private placement